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Fatigue is a frequent and distressing symptom in patients with multiple sclerosis (MS). In contrast,
sleepiness, characterized by difﬁculties to stay awake and alert during the day, seems to be less prevalent
in MS; however, exact studies are lacking. In addition, there is a semantic confusion of the concepts of
“fatigue” and “sleepiness”, which are often used interchangeably. We conducted a systematic review of
studies using the Epworth sleepiness scale (ESS) for the assessment of daytime sleepiness in patients
with MS. The summarized results of 48 studies demonstrate that sleepiness, as indicated by elevated ESS
scores, is less prevalent and less severe than fatigue but is present in a signiﬁcant proportion of patients
with MS. In most cross-sectional and longitudinal studies, there was a moderate association between ESS
scores and various fatigue rating scales. Longitudinal studies on the effect of wakefulness-promoting
agents failed to show a consistent improvement of sleepiness or fatigue as compared to placebo. It
has also been shown that daytime sleepiness is frequently associated with comorbid sleep disorders that
are often underrecognized and undertreated in MS. Sleepiness and potential sleep disorders may also
precipitate and perpetuate fatigue in patients with MS and should be part of the differential diagnostic
assessment. To support an appropriate decision-making process, we propose a stepwise evaluation of
sleepiness as compared to fatigue in patients with MS.
© 2016 Elsevier Ltd. All rights reserved.Introduction
Multiple sclerosis (MS) is an inﬂammatory, demyelinating and
neurodegenerative autoimmune disease of the central nervous
system (CNS) [1]. It is the leading cause of non-traumatic neuro-
logic disability in young adults [2]. MS is a chronic disease, whose
clinical course can be deﬁned as relapsing-remitting, primary-
progressive and secondary-progressive, and progressive-relapsing
(http://www.nationalmssociety.org) [3]. It involves a spectrum of
neurologic symptoms, such as sensory disturbances, impaired
vision, paresis, gait difﬁculties and bladder dysfunction. In addition,
fatigue, as well as cognitive decline, reﬂects the presence andand Psychotherapy, Center of
rsit€atsstrasse 84, D-93053,
x: þ49 (0) 941 941 1005.
etter).
tudy.
t al., Daytime sleepiness vers
ent tool, Sleep Medicine Revidistribution of damage in the CNS and may vary considerably
among individuals. MS-related fatigue is ascribed to multifactorial
etiologies including inﬂammatory cytokines, nocturia, pain, infec-
tion, anxiety and depression [4]. In addition, poor sleep and sleep
disorders, such as restless legs syndrome (RLS), have been identi-
ﬁed as contributing factors for MS-related fatigue and are more
common in MS patients compared to healthy controls [5,6].
It is reported that 53e92% of patients with MS are affected by
fatigue and as many as 46e66% suffer on a daily basis [7e12].
Fatigue is a disabling symptom that can be described as a feeling
of tiredness, exhaustion, weariness or lassitude. It is commonly
measured by self-rating scales such as the fatigue severity scale
(FSS) [13]. In about one third of the patients, fatigue may present
as the initial symptom of MS [14]. Overall, 28e60% of patients
report that fatigue is their most distressing symptom [12,14,15],
being a major cause of unemployment and early retirement in MS
[16,17]. Severe fatigue is also related to increased instances of
physical disability, neurological impairment and mobilityus fatigue in patients with multiple sclerosis: A systematic review on
ews (2016), http://dx.doi.org/10.1016/j.smrv.2016.03.004
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CBT cognitive behavioral therapy
CPAP continuous positive airway pressure
ESS Epworth sleepiness scale
FIS fatigue impact scale
FSMC fatigue scale for motor and cognitive functions
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(third edition)
IFN interferon
MFIS modiﬁed fatigue impact scale
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Fig. 1. Flow diagram of the study selection process. Legend: DIMDI: Deutsches Institut fü
mentation and information); MS: multiple sclerosis; ESS: Epworth sleepiness scale.
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fatigue) [16].
Fatigue is distinct from sleepiness, which is deﬁned by the In-
ternational classiﬁcation of sleep disorders (ICSD-3) as the inability
to stay awake and alert during the day, leading to episodes of an
irrepressible need for sleep or unintended lapses into drowsiness or
sleep [18] (Table 1). Sleepiness predisposes people to develop
serious performance impairments in daily functioning and is a risk
factor for potentially life-threatening domestic, occupational, and
vehicular accidents [18]. The complaint of excessive sleepiness
during the normal wake period is also a pivotal symptom for sleep
disorders of hypersomnolence, as classiﬁed by the ICSD-3.
Recently, sleep disorders in MS, as well as the causes and con-
sequences of daytime sleepiness in patients with MS, have gained
more attention in research, suggesting that sleepiness is an under-
recognized and overlooked symptom in MS. In contrast to the huge
body of literature on the presence of fatigue in MS, to our knowl-
edge, there is no systematic epidemiological study on the frequency
of sleepiness in MS.
The wide spectrum of fatigue prevalence rates in MS patients
may be due to the use of different assessment methods based on
various deﬁnitions and interpretations of the term “fatigue”. In
clinical practice as well as in the scientiﬁc literature, “fatigue” and
“sleepiness” are frequently used interchangeably [19]. Individualsch
ce 
n)
.
Study register search
155 records
ArƟcles excluded upon abstract review (n = 440) 
main causes for exclusion:
- no original data provided 
- no MS-parƟcipants
- only abstract available, no exisƟng
full-text arƟcle
- could not be obtained 
ArƟcles excluded upon full-text review (n = 38) 
main causes for stepwise exclusion:
- no use of the ESS as assessment (n = 21)
- no suﬃcient ESS data reported (n = 10)
- study sample size < 10 (n = 3) 
- age of parƟcipants < 18 years (n = 1)
- preliminary data of subsequently published
arƟcles  (n = 3)
DissertaƟon search
5 records
r Medizinische Dokumentation und Information (German institute of medical docu-
us fatigue in patients with multiple sclerosis: A systematic review on
ews (2016), http://dx.doi.org/10.1016/j.smrv.2016.03.004
Table 1
Comparison of fatigue and sleepiness as two different domains.
Fatigue Sleepiness
Deﬁnition “Fatigue is a subjective lack of physical and/or mental energy
that is perceived by the individual or the caregiver to interfere
with usual and desired activities.” (p. 2) [82].
“Sleepiness is the inability to stay awake and alert
during the major waking episodes of the day,
resulting in periods of irrepressible need for sleep
or unintended lapses into drowsiness or sleep.” (p.
143) [18].
Symptoms  Feelings of tiredness, exhaustion, weariness or lassitude.
 Not necessarily associated with sleep pressure.
 No deﬁnite sleep drive when resting (e.g., lying down to
relax).
 Decreased level of alertness or wakefulness.
 Increased tendency to fall asleep or doze off
unintentionally.
 Sleep drive when resting (e.g., lying down to
nap).
Semantics  Tiredness is commonly used as synonym (e.g., by
insomniacs).
 Tiredness is commonly used as synonym (e.g.,
by narcoleptics).
Characteristics in MS  Common and most troublesome symptom.
 Strong negative impact on social and occupational
functioning.
 Not commonly associated with MS.
 Often associated with sleep disorders.
Assessment by common rating scales Fatigue severity scale (FSS)
- Most widely used validated scale.
- Evaluates the impact on motivation, physical abilities and
social functioning.
- Self-administered, nine items.
- 7-point Likert scale from 1 (strongly disagree) to 7
(strongly agree).
- Critical cut-off: mean FSS score >4 (min: 1; max: 7) or
total FSS score 36 (min: 9; max: 63).
Epworth sleepiness scale (ESS).
- Most commonly used scale in sleep research
and clinical settings.
- Assessment of sleep propensity
- Self-administered, 8-item questionnaire.
- 4-point Likert scale (from 0 to 3) to rate the
likelihood of dozing off in eight everyday
situations.
- Critical cut-off: total ESS score >10 (min: 0;
max: 24).
Objective assessments  No validated measures available.  Maintenance of wakefulness test; multiple
sleep latency test; EEG; pupillography.
 Psychomotor vigilance task; sustained
attention and vigilance tasks; driving
simulator.
Counter-measures  Alleviated by periods of rest, unlike weakness (asthenia).
 Limited efﬁcacy of stimulants.
 Most effective: sleep or short naps, but not
rest.
 Stimulants temporarily effective.
EEG: electroencephalography; ESS: Epworth sleepiness scale; FSS: fatigue severity scale; MS: multiple sclerosis.
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Nevertheless, “fatigue”, “sleepiness” or “tiredness” refer to distinct
concepts and provide different semantic connotations [20]. The
need to distinguish between fatigue and sleepiness is supported by
other studies showing that both conditions substantially differ in
implications for diagnosis and treatment, subjective experience,
and their underlying neurobiological mechanisms [19,21,22].
A widely used approach to evaluate daytime sleepiness on a
subjective level is the employment of the Epworth sleepiness scale
(ESS), a self-administered 8-item questionnaire assessing sleep
propensity [23]. A total ESS score greater than 10 (range 0e24) is
indicative for increased sleepiness. In the instructions, the ESS asks
for the likelihood of dozing off or falling asleep in different
everyday situations, “in contrast to feeling just tired“ [23]. Thus, the
ESS quantiﬁes daytime sleepiness using behavioral correlates and
circumvents subjective evaluations of states of tiredness, sleepiness
or fatigue. Assessing sleepiness by this approach avoids semantic
confusion, which is a problem when using fatigue questionnaires
that are based on self-reports.
The aim of this systematic review is to summarize the results of
published studies using the ESS for the assessment of daytime
sleepiness in patients with MS. We focused on the frequency and
extent of daytime sleepiness compared to fatigue as assessed by
self-administered rating scales such as the FSS or other related
scales (e.g., neurological fatigue index (NFI-MS), modiﬁed fatigue
impact scale (MFIS)).
Methods
Literature search and identiﬁcation of studies
Studies were identiﬁed by searching electronic databases and
scanning reference lists of articles. The present review onlyPlease cite this article in press as: Popp RFJ, et al., Daytime sleepiness vers
the Epworth sleepiness scale as an assessment tool, Sleep Medicine Reviincludes studies that used the ESS, which was published in 1991,
as an assessment-tool. Therefore, articles that were published
before 1991 were not considered. No other limits (e.g., language
restrictions) were applied. The search strategy was developed by a
subject specialist (RP) in collaboration with an information
specialist and librarian who is trained and experienced in con-
ducting comprehensive literature searches (HK). Database
searches were conducted by HK on May 14, 2014, with an update
on April 22, 2015. In addition, registers for clinical trials were
searched on August 04, 2015. While our search strategy was not
peer-reviewed, we strived to design, carry out and report the
literature search according to current checklists and recommen-
dations [24,25].
The research question was translated into two search concepts,
“multiple sclerosis” and “Epworth sleepiness scale” that were
combined using the Boolean operator AND. The search strategywas
adapted to the various databases and search interfaces. This
included selecting feasible search terms, syntax, and relevant
subject headings. The searches were designed to be sensitive and
potentially over-inclusive to avoid missing any relevant articles. We
searched 28 medical and psychological reference databases hosted
by DIMDI (Deutsches Institut für Medizinische Dokumentation und
Information [German institute of medical documentation and
information]), including MEDLINE, Embase, Cochrane database of
systematic reviews, and Cochrane central register of controlled
trials. In addition, a full text search was conducted in PubMed
central. In Web of Science core collection, we searched for studies
on MS that cite the original article about the “Epworth sleepiness
scale” by Johns, [23]. Several dissertation databases and four reg-
isters for clinical trials were also consulted.
A detailed documentation of the searches allowing for replica-
tion, can be seen in Appendix 1, which is available as an electronicus fatigue in patients with multiple sclerosis: A systematic review on
ews (2016), http://dx.doi.org/10.1016/j.smrv.2016.03.004
Table 2
Summarized studies using the Epworth sleepiness scale (ESS) as an assessment tool in patients with multiple sclerosis (MS).
Authors, year
[reference]
N MS-patients
(n controls)
N MS-patients
in subgroups
Age (y) mean (SD)
median* [range]
Sex
female %
ESS mean (SD)
median*
[range]
ESS >10 (%) Fatigue score
mean (SD)
median* [range]
Signiﬁcant
correlation
ESS  fatigue score
Study
design
Main outcome
Cross-sectional studies
Attarian
et al., 2004 [26]
30 (15) 15 fatigue
15 non-fatigue
46.4 ()
33.5 ()
73%
total
12* [2e24]
5* [0e19]
60%
13%
7* [5e11]
3* [1e4]
r not reported
p ¼ .02
CS
CC
Signiﬁcant correlation between
fatigue and disrupted sleep/
abnormal sleep cycles in MS
assessed by actigraphy.
Beran
et al., 2008 [27]
12 (14) 6 sleepiness
6 non-sleepiness
47.8 ()
total
83%
total
15.0 (4.4)
4.8 (3.1)
e
e
5.1 (1.7)
3.4 (1.4)
e CSPSG
CC
Signiﬁcant relationship
between PLMS with arousals
and increased sleepiness
Braley
et al.þ 2012 [28]
30 (30) Total 46.7 (11.3) 70% 11.3 (4.9) e e n.s. CSPSG
CC
Fatigue, tiredness, and lack of
energy, but not sleepiness, are
more frequent in MS compared
to controls.
Braley
et al., 2014 [29]
195 Total
110 elevated OSA risk
85 no elevated OSA risk
154 OSA not conﬁrmed
41 diagnosed OSA
47.1 (12.1)
50.3 (11.8)
43.0 (11.1)
45.8 (12.2)
52.1 (10.4)
66%
53%
82%
68%
59%
8.1 (5.1)
9.1 (5.0)
6.9 (5.1)
7.9 (5.0)
9.0 (5.6)
e
e
e
e
e
4.6 (1.8)
5.1 (1.6)
4.0 (1.8)
4.5 (1.8)
5.0 (1.6)
FSS
r ¼ 0.44;
p < .0001
CS
CC
Sleep disturbances, especially
OSA, are frequent in MS and
may contribute to fatigue..
Braley
et al., 2015 [30]
190 Total
121 fatigue
69 non-fatigue
47.0 (12.2)
47.6 (11.5)
46.4 (13.3)
67%
65%
71%
8.2 (5.1)
9.4 (5.3)
5.8 (4.0)
e
e
e
4.6 (1.8)
5.7 (0.9)
2.5 (0.8)
e CS 47% of MS patients use
hypnotics; carry-over effects
may be involved in fatigue
Brass
et al., 2014 [31]
2375 Total 54.7 (12.4) 81% 8* [0e24] 30% 45* [6e63] e CS The majority of MS patients are
affected by one or more sleep
disorders, often undiagnosed.
Bøe Lunde
et al.þ 2012 [32]
90 (108) Total (73 with valid ESS)
24 good sleepers
49 poor sleepers
45.0 (10.4)
43.2 (12.0)
46.2 (10.4)
54%
38%
65%
8.6 (4.6)
e
e
34%
22%
42%
e
e
e
e CS
CC
Poor sleep is common in MS.
Treatment may improve sleep
and quality of life.
Chen
et al., 2014 [33]
21 (11) 11 fatigue
10 non-fatigue
30.9 (11.0)
26.8 (4.1)
73%
70%
15.7 (7.2)
9.0 (2.8)
38%- 50.8 (6.1)
26.1 (6.4)
FSS
r ¼ 0.74; p < .001
CSPSG
CC
Sleep disorders and excessive
daytime sleepiness are more
common in MS.
Constantinescu
et al., 2011 [34]
34 24 valid ESS data 41.5**
[36e49]
58% 10**
[5.3e14.5]
e 5.4**
[4.4e6.1]
FSS
r ¼ 0.47; p ¼ .019
CS
CC
No evidence of orexin A
deﬁciency in MS but in other
CNS inﬂammatory diseases
Dias
et al., 2012 [35]
103 Total 45.8 (11.0) 72% 7.3 (4.8) 23% 4.6 (1.6) FSS
r ¼ 0.31; p < .01
CS Over 40% of MS patients show
elevated OSA risk.
Elkattan
et al., 2009 [36]
20 (10) 10 fatigue
10 non-fatigue
27.7 (6.5)
28.8 (6.7)
e
e
7.2 (4.0)
5.3 (4.2)
e
e
27.7 (6.5)1
28.8 (6.7)1
e CSPSG
CC
Sleep parameters do not
distinguish between fatigued
and non-fatigued MS patients
Frauscher
et al., 2005 [37]
61 (42) Total 34.5 (8.3) 53% 7.4 (3.5) 26% e e CS
CC
No increased daytime
sleepiness in MS compared to
controls
Ghajarzadeh
et al., 2012 [38]
100 64 fatigue
36 non-fatigue
34.0 (8.4)
28.4 (8.3)
73%
78%
3.8 (3.1)
3.6 (3.1)
6%
6%
35.3 (17.6) 05
19.1 (16.5) 05
MFIS
r ¼ 0.33; p ¼ .001
CS Signiﬁcant correlations
between fatigue scores and
depression, sleep quality, and
ESS
Heesen
et al., 2006 [39]
30 15 fatigue
15 non-fatigue
46.6 (11.7)
42.9 (10.2)
60%
60%
10.5 (4.7)
3.3 (2.4)
e
e
6.1 (0.7)
1.5 (0.7)
e CS Fatigue in MS may be
inﬂuenced by increased levels
of inﬂammatory cytokines.
Kaminska
et al., 2012 [40]
62 (32) Total 47.3 (10.4) 73% 8.4 (4.4) 34% 5.1 (1.6) FSS
r ¼ 0.31; p ¼ .002
CSPSG
CC
OSA is common in MS and
related to fatigue, but not to
sleepiness.
Kaynak
et al., 2006 [41]
37 (13) 27 fatigue
10 non-fatigue
37.4 (8.7)
36.5 (8.4)
59%
50%
4.4 (2.8)
3.3 (3.0)
7%
0%
5.5 (0.9)
<4
n.s. CSPSG
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Sleep fragmentation observed
in MS patients can be involved
in MS fatigue.
Kister
et al., 2010 [42]
167 94 migraineurs
73 no headache
43 (11.0)
47 (13.0)
90%
57%
8.1 ()
5.6 ()
e
e
5.0 ()
3.6 ()
e CS Migraine in MS is more
frequent than in the general
population.
Knudsen
et al., 2008 [43]
48 MS and MON Total [21e57] 71% 5.6 (2.9) 10% e e CS Intact hypocretin system in
both subgroups, no increased
sleepiness
Kotterba
et al., 2003 [44]
31 Total 35.6 (8.3) 58% 6.1 (2.9) 10% 4.3 (1.6) FSS
r ¼ 0.42; p < .05
CS Terms ”sleepiness” and
“fatigue” are often confused,
but different scales allow for
differentiation
Labuz-Roszak
et al., 2012 [45]
122 Total 37.7 (10.8) 71% 6.3 (3.9) 21% 40.6 (14.8)1 FSS
r ¼ 0.18; p ¼ .03
CS Fatigue is frequent in MS and
moderately correlated with
depression and anxiety.
Merkelbach
et al., 2011 [46]
80 Total 43.2 (9.8) 71% 8.1 (3.7) e 4.4 (1.6) FSS
r ¼ 0.42; p < .001
CS Physical activity correlates with
disease severity, but not with
fatigue or sleepiness.
Mills and Youngþ
2011 [47]
635 559 valid ESS data 46.6 (10.9) 71% 7.9 (4.5) e e n.s. CS Fatigue is correlated with
disability, disease type and
sleep duration (u-shaped
correlation).
Moreira
et al., 2008 [48]
44 32 RLS
12 non-RLS
40.7 (14.8)
44.1 (13.4)
67%
75%
5.7 (4.0)
5.7 (3.0)
7%
total
e
e
n.s. CS MS patients with RLS show
greater disability, poorer sleep
and increased levels of fatigue.
Neau
et al., 2012 [49]
205
25 with PSG
Total questionnaire
8 fatigue þ sleepiness
17 fatigue, non-sleepiness
43.7 (11.1)
40.1 (11.2)
39.7 (9.3)
76%
63%
59%
7.3 (4.8)
14.7 (0.5)
4.6 (2.1)
31%
e
e
81.6 (34.2) 03
118.2 (23.8) 03
65.6 (33.1) 03
FIS
r ¼ 0.68
subgroups p < .0001
CSPSG Sleep disturbances and
excessive daytime sleepiness
are frequent in MS.
Neumann
et al., 2014 [50]
35 (15) 30 fatigue
5 non-fatigue
44.7 (7.1)
45.3 (6.1)
73%
40%
8.2 (2.1)
5.4 (3.0)
0%x
e
75.6 (13.5) 04
49.4 (10.6) 04
e CS Reaction time is an objective
marker for fatigability.
Niepel
et al.þ 2013 [51]
26 (9) Total
17 fatigue
9 non-fatigue
e
49.4 (9.2)
41.8 (13.1)
65%
71%
56%
5.6 (4.1)
7.0 (3.8)
3.0 (3.7)
15%
e
e
e
e
e
r ¼ 0.41
p ¼ .039 in fatigued
patients
CS
CC
Fatigued MS patients have
reduced levels of alertness and
sympathetic activity. Modaﬁnil
shows alerting and
sympathomimetic short-term
effects.
Papuc
et al., 2010 [52]
38 (15) Total
10 fatigue
28 non-fatigue
36* [21e68]
34* [21e69]
38* [22e55]
53%
54%
60%
6* [2e11]
6* [2e11]
6* [4e8]
e
e
e
5.5* [1.7e6.6]
5.7* [4.8e6.6]
2.6* [1.7e4.1]
e CS
CC
CSF hypocretin-1 levels do not
differ between MS and controls,
but are correlated with fatigue
levels.
Pokryszko-Dragan
et al., 2013 [53]
100 Total
49 fatigue
51 non-fatigue
42 [20e67]
e
e
69%
e
e
6.3 [0e19]
6.4 (3.9)
6.2 (4.7)
19%
e
e
3.8 [1.1e7.0]
e
e
n.s. CS Sleep disturbances may
increase fatigue and are related
to MS symptoms and therapies.
Sauter 2004 [54] 30 Total 40.4 (9.2) 67% 9.7 (4.2) 13% 5.2 (1.1) n.s. CS
CC
MS patients differ from controls
in sleep efﬁciency, sleep quality,
and quality of life.
Stanton
et al., 2006 [55]
60 Total 41* [19e69] 72% 7* [0e19] 32% 11* [2.5e15.8] FSS
r ¼ 0.30; p ¼ .022
CS Sleep disturbances are frequent
in MS and may contribute to
fatigue.
Veauthier
et al., 2011 [56] (2013) [73]
141 66 PSG total
26 fatigue
40 non-fatigue
75 no PSG total
21 fatigue
54 non-fatigue
43.2 (10.0)
45.3 (9.5)
42.0 (10.2)
45.4 (10.8)
44.5 (10.6)
45.9 (10.9)
68%
73%
65%
67%
55%
72%
8.9 (4.7)
11.3 (4.2)
7.5 (4.5)
8.2 (4.6)
9.8 (4.4)
7.6 (4.5)
e
e
e
e
e
e
4.5 (1.8)
6.0 (1.0)
3.6 (1.6)
4.8 (1.7)
5.9 (1.0)
4.4 (1.7)
e CSPSG Signiﬁcant relationship
between sleep disorders and
fatigue in MS
Wunderlin
et al., 1997 [57]
10 Total 45.0 (8.0) 80% 9.2 (5.3) 40% 4.5 (1.7) e CS Fatigue and daytime sleepiness
cannot be explained by
nocturnal apneas or oxygen
desaturations.
(continued on next page)
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Table 2 (continued )
Authors, year
[reference]
N MS-patients
(n controls)
N MS-patients
in subgroups
Age (y) mean (SD)
median* [range]
Sex
female %
ESS mean (SD)
median*
[range]
ESS >10 (%) Fatigue score
mean (SD)
median* [range]
Signiﬁcant
correlation
ESS  fatigue score
Study
design
Main outcome
Longitudinal studies
Attarian
et al., 2011 [58]
29 15 placebo
14 eszopiclone
46.5 [31e58]
45.0 [25e64]
80%
87%
12.5 (4.3)
9.9 (3.6)
e
e
11.1 (2.2) 02
7.9 (2.8) 02
e LS
CC, PC
Eszopiclone increases total
sleep time, but does not
improve fatigue in MS.
Brioschi
et al., 2009 [59]
12 Total 43.3 (9.3) 92% 9.3 (3.9) e 5.6 (0.9) 01 e LS Modaﬁnil improves fatigue in
MS, no changes in physical
activity
Bruce
et al., 2012 [60]
30 16 after placebo (phase I)
14 after placebo (phase II)
49.9 (7.2)
47.7 (6.0)
88%
79%
9.3 (4.3)
9.7 (5.0)
e
e
18.6 (10.2) 05
17.8 (8.4) 05
e LS
PC
Armodaﬁnil improves delayed
verbal recall, no other changes
in other outcome parameters.
Co^te
et al., 2013 [61]
62 21 SLD treated
18 SLD untreated
17 no SLD
51.3 (8.3)
49.8 (8.8)
41.9 (10.7)
62%
78%
77%
9.6 (3.8)
7.6 (4.9)
7.9 (4.8)
e
e
e
5.1 (1.6)
5.4 (1.5)
4.8 (1.8)
e LSPSG Treatment of OSA and RLS
improves fatigue in MS.
García Jalon
et al., 2013 [62]
23 10 MS control
13 MS intervention
52.0 (7.0)
45.9 (9.9)
60%
77%
12.4 (4.5)
6.9 (4.1)
e
e
5.9 (0.9)
5.6 (0.6)
e LS High acceptance of an energy
conservation program by MS
patients
Gerhard 2009 [63] 30 Total 36.0 (10.4) 67% 8.4 (3.7) 37% 35.2 (16.9)1 e LS IFNb1a treatment increases
fatigue and improves cognitive
functions.
Kallweit
et al., 2013 [64]
69 Total
28 SRBD
41 non-SRBD
49.8 (9.2)
53.3 (9.5)
47.4 (8.3)
70%
57%
78%
e
9.7 (3.8)
9.4 (4.7)
e
61%
44%
e
5.5 (0.9)
5.7 (0.7)
e LS High prevalence of SRBD in MS
patients; continuous positive
airway pressure therapy
decreases fatigue but not
sleepiness.
Mendozzi
et al., 2010 [65]
42 Total
12 no-IMA
10 glatiramer acetate
10 IFNb1a/b s.c.
10 IFNb1a/b i.m..
39.4 (7.4)
41.8 (5.7)
38.6 (8.4)
38.5 (9.9)
38.2 (5.4)
e
e
e
e
e
5.7 (3.2)
6.3 (3.6)
6.8 (2.5)
4.8 (2.7)
4.9 (3.6)
14%
e
e
e
e
3.6 (1.8)
3.4 (1.6)
4.4 (1.7)
4.1 (1.9)
2.7 (1.6)
e LS IFNb and glatiramer acetate
treatment decrease sleep
efﬁciency in MS assessed by
actigraphy
M€oller
et al., 2011 [66]
121 59 placebo
62 modaﬁnil
40.8 (11.2)
41.4 (9.5)
78%
63%
11.8 (5.0)
11.8 (4.9)
e
e
5.8 (0.8)
6.0 (0.8)
e LS
PC
No effect of modaﬁnil on fatigue
in MS
Rammohan
et al., 2002 [67]
72 Total 44.0 [23e61] 75% 9.5 [1e20] e 5.9 [4e7] e LS
PC
Modaﬁnil signiﬁcantly
improves fatigue.
Stankoff
et al., 2005 [68]
115 59 placebo
56 modaﬁnil
44.0 (9.0)
43.8 (8.0)
e
e
9.7 (5.5)
10.6 (4.8)
53%
total
63.1 (9.3) 05
63.3 (10.0) 05
e LS
PC
No differences between effects
of modaﬁnil and placebo
treatment on fatigue in MS
Svenningsson
et al., 2013 [69]
195 Total 39.7 (9.2) 71% 8.8 () e 71.2 () 04 e LS Natalizumab improves fatigue,
sleepiness, quality of life,
depression, and cognition.
Vakhapova
et al., 2010 [70]
16 Total 45.4 [26e60] e 6.4 (5.6)
after placebo
e 37.4 (15.8)1
after placebo
e LS
PC
Sublingual tizanidine improves
daytime sleepiness and
spasticity in MS
Van Kessel
et al.þ 2008 [71]
72 35 CBT
37 relaxation training
42.9 (9.3)
47.0 (9.5)
80%
70%
6* [-]
5* [-]
e
e
20.91 (4.3)
20.31 (4.3)
e LS
CC
Both CBT and relaxation
training are effective
treatments for fatigue in MS;
CBT is more effective.
Zifko
et al., 2002 [72]
50 Total 40.4 (10.3) 60% 9.7 (3.9) e 30.3 (8.5)1 e LS Modaﬁnil treatment improves
fatigue and sleepiness in MS.
Symbols: *median; ** median [interquartile range]; ~ longitudinal study; þ data provided on request; PSG use of PSG; x ESS score >10 exclusion criterion; - data not reported.
Statistics: F/non-F: subdivision in fatigued and non-fatigued subgroups; n: number of participants; n.s.: not signiﬁcant; p: p-value; r: correlation coefﬁcient; SD: standard deviation.
Fatigue Scales: FSS: fatigue severity scale (cut off >4); 1 FSS total score (cut off >36).
Other Fatigue Scales: 01 FAI: fatigue assessment inventory (cut off 4); 02 FDS: fatigue descriptive scale (cut off >5); 03 FIS: fatigue impact scale; 04 FSMC: fatigue scale for motor and cognitive functions (mild fatigue 43;
moderate fatigue 53; severe fatigue 63); 05 MFIS: modiﬁed fatigue impact scale (cut off >34).
Abbreviations: CBT: cognitive behavioral therapy; CC: case-controlled; CS: cross-sectional study; IFN1b1a/b s.c.: interferon-beta 1a or interferon-beta 1b for subcutaneous injection; IFNb1a/b i.m.: interferon-beta 1a or
interferon-beta 1b injected intramuscularly; LS: longitudinal study; MON: monosymptomatic optic neuritis; no-IMA: no treatment with immunomodulant agents; OSA: obstructive sleep apnea; PC: placebo-controlled; PLMS:
periodic limb movements in sleep; PSG: polysomnography; RLS: restless legs syndrome; SLD: sleep disorders; SRBD: sleep-related breathing disorder.
Boldfaced numerals denote scores above critical cut offs (e.g., ESS >10; FSS >4); Italic printed numerals mark fatigue scores other than FSS score.
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Table 3
Additional information on longitudinal studies using the Epworth sleepiness scale (ESS) as an assessment tool in patients with multiple sclerosis (MS).
Authors, year
[reference]
N MS-patients ESS baseline mean
(SD) median*
[range]
ESS follow-up/
intervention
mean (SD)/median*
[range]
Fatigue baseline
mean (SD)
Fatigue follow-up/
intervention
mean (SD)
Follow-up
period to baseline
Intervention Intervention efﬁcacy
Attarian
et al., 2011 [58]
15 placebo
14 eszopiclone
12.5 (4.3)
9.9 (3.6)
10.5 (3.9)
8.2 (4.0)
11.1 02 (2.2)
7.9 02 (2.8)
5.4 02 (3.1)
4.6 02 (3.6)
7 wk Eszopiclone or placebo n.s. ESS and FSS
changes
Brioschi
et al., 2009 [59]
12 9.3 () T1: 9.1 (3.0)
T2: 10.4 (4.7)
5.6 01 (0.9) T1: 4.5 01 (1.1)
T2: 5.1 01 (1.1)
T1: 3 mo with modaﬁnil
T2: 1 mo without modaﬁn
Modaﬁnil n.s. ESS changes;
signiﬁcant FAI
improvements T0 to T1
(D1.1)
Bruce
et al., 2012 [60]
16 placebo ﬁrst
14 armodaﬁnil ﬁrst
9.3 (4.3)
9.7 (5.0)
9.2 (5.0)
10.5 (4.3)
18.6 05 (10.2)
17.8 05 (8.4)
18.2 05 (10.6)
18.6 05 (10.5)
1 wk change
(cross-over design)
Armodaﬁnil n.s. ESS and FSS
changes
Co^te
et al., 2013 [61]
21 SLD, treated
18 SLD, untreated
17 no SLD
9.6 (3.8)
7.6 (4.9)
7.9 (4.8)
6.1 (3.8)
7.1 (5.5)
7.2 (4.2)
5.1 (1.6)
5.4 (1.5)
4.8 (1.8)
4.5 (1.7)
5.1 (1.5)
5.2 (1.2)
3 mo Treatment of OSA and
RLS
Signiﬁcant FSS (D0.9),
MFI 06, ESS and PSQI
improvements
García Jalon
et al., 2013 [62]
10 MS control
13 MS intervention
12.4 (4.5)
6.9 (4.1)
T1: 10.2 (4.3)
T2: 14.0 (10.7)
T3: 10.6 (4.2)
T1: 6.6 (4.2)
T2: 6.5 (4.9)
T3: 6.9 (4.1)
5.9 (0.9)
5.9 (0.6)
T1: 4.9 (1.0)
T2: 5.5 (0.9)
T3: 4.9 (1.3)
T1: 5.0 (1.4)
T2: 4.7 (1.7)
T3: 5.2 (1.3)
T1: intervention
T2: 6 wk
T3: 3 mo
Energy conservation
program
n.s. ESS, FSS and FIS
changes; signiﬁcant FIS
Cognitive
improvements (D5.8)
Gerhard
2009 [63]
30 8.4 (3.7) 10.2 (4.4) 35.21 (16.9) 38.81 (16.8) 6 mo Interferon Signiﬁcant ESS (D1.6)
and FSS (D3.6) decline
Kallweit
et al., 2013 [64]
28 SRBD
41 non-SRBD
9.7 (3.8)
9.4 (4.7)
9.5 (3.0)
-
5.5 (0.9) 5.7 (0.7) 4.8 (0.6)
-
6 mo OSA treatment n.s. ESS changes;
signiﬁcant FSS
improvements (D1.0)
Mendozzi
et al., 2010 [65]
42 total
12 no-IMA
10 GA
10 IFNb1a/b s.c.
10 IFNb1a/b i.m.
5.7 (3.2)
6.3 (3.6)
6.8 (2.5)
4.8 (2.7)
4.9 (3.6)
5.6 (3.9)
6.4 (3.9)
7.6 (3.6)
4.8 (4.4)
3.5 (2.5)
3.6 (1.8)
3.4 (1.6)
4.4 (1.7)
4.1 (1.9)
2.7 (1.6)
3.7 (1.7)
3.5 (1.3)
4.5 (1.9)
4.0 (1.6)
2.8 (1.6)
seven nights No-IMA, GA, IFNb1a/b
s.c., IFNb1a/b i.m.
n.s. ESS and FSS
changes
M€oller
et al., 2011 [66]
62 modaﬁnil
59 placebo
11.8 (4.9)
11.8 (5.0)
9.7 (4.4)
9.5 (4.9)
6.0 (0.8)
5.8 (0.8)
5.3 (1.2)
5.4 (1.0)
8 wk Modaﬁnil n.s. ESS, FSS and MFIS
changes
Rammohan
et al., 2002 [67]
72 9.5 [1e20] T1: 7.2 ()
T2: 7.0 ()
T3: -
5.9 [4e7] T1: 4.7 ()
T2: 5.3 ()
T3: 5.3 ()
T1: 2 wk 200 mg modaﬁn
T2: 4 wk (2 wk 400 mg)
T3: 7 wk (3 wk placebo
washout)
Modaﬁnil T1: signiﬁcant ESS
(D2.3) and FSS (D0.8)
improvements;
T2: signiﬁcant ESS
improvements (D2.5);
n.s. FSS changes
Stankoff
et al., 2005 [68]
56 modaﬁnil
59 placebo
10.6 (4.8)
9.7 (5.5)
e 63.3 03 (10.0)
63.1 03 (9.3)
52.3 05 (18.5)
49. 2 05 (16.6)
35 d Modaﬁnil Signiﬁcant MFIS
improvements for both
groups (modaﬁnil:
D11.0 vs. placebo:
D13.9), but no beneﬁt of
modaﬁnil compared to
placebo
Svenningsson
et al., 2013 [69]
143 8.8 () 7.5 () 71.2 04 () 62.2 04 () 12 mo Natalizumab Signiﬁcant ESS (D1.33)
and FSMC (D9.0)
improvements
Vakhapova
et al., 2010 [70]
16 6.4 (5.6)
after placebo phase
4.8 (4.6) s.l.
5.5 (4.6) oral
37.41 (15.8)
after placebo phase
33.61 (16.8) s.l.
34.11 (17.0) oral
7 d placebo phase and 7 d
of each condition
(cross-over design)
Tizanidine Signiﬁcant ESS
improvements (D1.6
only for s.l. application
vs. placebo)
(continued on next page)
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Table 3 (continued )
Authors, year
[reference]
N MS-patients ESS baseline mean
(SD) median*
[range]
ESS follow-up/
intervention
mean (SD)/median*
[range]
Fatigue baseline
mean (SD)
Fatigue follow-up/
intervention
mean (SD)
Follow-up
period to baseline
Intervention Intervention efﬁcacy
Van Kessel
et al.þ 2008 [71]
35 CBT
37 relaxation training
6* [-]
5* [-]
T1: 3* [e]
T2: 3* [e]
T3: 3* [e]
T1: 6* [e]
T2: 4* [e]
T3: 4* [e]
20.91 (4.3)
20.31 (4.3)
T1: 7.91 (4.3)
T2: 9.01 (5.3)
T3: 10.41 (6.4)
T1: 11.61 (5.3)
T2:11.11 (4.6)
T3:12.51 (5.2)
T1: 2 mo (post treatment)
T2: 5 mo
T3: 8 mo
CBT vs. relaxation
training
Signiﬁcantly greater
fatigue reductions in
the CBT group across
the 8 mo compared to
the relaxation training
group
Veauthier
et al., 2013 [73]
58 total
13 good compliance
12 moderate
compliance
17 no compliance
4 no feedback
12 no sleep disorder
9.1 (4.6)
9.5 (5.9)
9.8 (4.8)
10.8 (3.7)
6.0 (4.5)
6.4 (2.9)
8.5 (4.6)
9.4 (5.9)
9.3 (5.9)
10.2 (2.9)
6.8 (3.3)
5.7 (2.5)
4.7 (2.3)
4.8 (1.1)
5.5 (3.9)
4.8 (1.7)
4.9 (1.5)
3.3 (1.5)
4.0 (1.8)
4.3 (1.5)
3.9 (2.2)
4.4 (1.7)
3.2 (1.9)
3.4 (1.6)
16 mo (median) Treatment of sleep
disorders
n.s. ESS changes;
signiﬁcant FSS
improvements on in
the entire cohort (D0.7),
but n.s. changes in
subgroups; signiﬁcant
MFIS improvements in
good compliance
subgroup (D15)
Zifko et al., 2002 [72] 50 9.7 (3.9) 4.9 (2.9) 30.31 (8.5) 25.41 (3.7) 3 mo Modaﬁnil Signiﬁcant ESS (D4.8)
and FSS (D4.9)
improvement
Statistics: n: number of participants; n.s.: not signiﬁcant; SD: standard deviation; T1-3: times of assessment; D: changes; - data not reported.
Fatigue Scales: FSS: fatigue severity scale (cut off >4); 1 FSS total score (cut off >36).
Other Fatigue Scales: 01 FAI: fatigue assessment inventory (cut off  4); 02 FDS: fatigue descriptive scale (cut off >5); 03 FIS: fatigue impact scale; 04 FSMC: fatigue scale for motor and cognitive functions (mild fatigue 43;
moderate fatigue 53; severe fatigue 63); 05 MFIS: modiﬁed fatigue impact scale (cut off >34/45); 06 MFI: multidimensional fatigue inventory.
Abbreviations: CBT: cognitive behavioral therapy; GA: glatiramer acetate; IFNb1a/b s.c.: interferon-beta 1a or interferon-beta 1b for subcutaneous injection; IFNb1a/b i.n. interferon-beta 1a or interferon-beta 1b injected
intramuscularly; no-IMA: no treatment with immunomodulant agents; OSA: obstructive sleep apnea; PSQI: Pittsburgh sleep quality index; RLS: restless legs syndrome; SRBD: sleep-related breathing disorder; SLD: sleep
disorders; s.l.: sublingual.
Boldfaced numerals denote scores above critical cut offs (e.g., ESS >10; FSS >4); Italic printed numerals mark fatigue scores measured with fatigue scales other than FSS.
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R.F.J. Popp et al. / Sleep Medicine Reviews xxx (2016) 1e14 9supplement. The reference lists of articles that were regarded
eligible were scanned by AF, NK, and RP.
Eligibility assessment
Eligibility assessment was performed independently in a stan-
dardized manner by three reviewers (RP, AF, and NK). Disagree-
ments were solved by consensus. If no agreement could be reached,
another author (TW) was designated to make the ﬁnal decision.
Studies were included only if they contained the following: a)
original investigations - articles in which no original data was
published were excluded (e.g., mostly reviews, letters to the editor
etc.) b) published ESS data e the article had to provide statistical
data of the ESS score (e.g., mean, median) c) adult (18 y) patients
with MS d) sufﬁcient sample sizes, (n  10) that allowed for
inferential statistics, i.e., no case reports or studies providing only
descriptive data. Finally, no restrictions concerning duration of
illness, subtype of MS or other speciﬁcations were applied. We also
did not limit this review to studies with special interventions.
Data extraction
A data-extraction sheet was developed and pilot-tested on 10
pseudo-randomly selected articles. After applying some adaptive
changes, it was used for extracting information from all included
studies (see Table S1 - Appendix 3). The data extraction was per-
formed by one of the authors (AF) and examined by another (NK). If
therewere any ambiguities concerning the data, theywas discussed
by a committee of three additional authors (RP, RW, and TCW). From
each studyweextracted the informationpresented inTables 2 and3.
Results
Study selection
Disagreements regarding eligibility assessment between the
reviewers (AF, RP, and NK) were minor and could be resolved by
consensus. Our cross-database search yielded 607 records. After
removing duplicates, 521 records remained and were screened for
relevance. 440 recordswere excluded because no original datawere
published, disorders other than MS were investigated (e.g., sleep
disorders, Parkinson's disease), or there were no ESS data speciﬁed
in the abstract and no full text articles were available. If the record
was categorized as potentially relevant, the full text article was
assessed for eligibility. 21 studieswere not included because the ESS
was not used as an assessment tool. In three studies, the number of
participants was too small (<10) to be included. One of the full text
articles was excluded because the patients were younger than 18
y of age. Ten of the full text articles were excluded because no
sufﬁcient statistical ESS data were published. However, if the cor-
responding author of these studies could provide ESS data on
request, the articles were included in the study selection (n¼ 5; see
supplementary material - Appendix 2). Finally, our systematic re-
view comprised 48 studies (Table 2) [26e73].
The ﬂow diagram of the selection process is presented in Fig. 1.
Detailed information on articles excluded by full-text review is
given in Appendix 4 of the supplementary material.
Review ﬁndings
No systematic epidemiological studies on the prevalence of
daytime sleepiness in MS patients using the ESS as a main outcome
parameter have been published so far. Out of 48 original articles,
about one-third (30%) of the studies comprised a larger MS sample
size, i.e., at least 100 patients were included. Themajority of articlesPlease cite this article in press as: Popp RFJ, et al., Daytime sleepiness vers
the Epworth sleepiness scale as an assessment tool, Sleep Medicine Revi(67%) had a cross-sectional study design, while the others, in most
cases, used a long-term longitudinal study design to assess
different treatment effects of medication and other interventions
such as treatment of sleep disorders [58e72]. In particular, two
studies investigated the effect of continuous positive airway pres-
sure (CPAP) treatment on respiratory disturbances occurring during
sleep, which are deﬁned as sleep-related breathing disorder (SRBD)
[61,64]. As the ESS and FSS are trait-speciﬁc questionnaires, po-
tential improvements of both scores depend on lasting in-
terventions (i.e., from one week to several months). Thus, we did
not consider temporary pharmacological effects lasting only a few
hours as longitudinal data [51]. We also used baseline results of
longitudinal studies to gain cross-sectional data on ESS and fatigue
scores. Out of all investigations, 19 studies provided data on the
correlation between the ESS and the FSS (89%) or other fatigue
scales (e.g., NFI-MS, MFIS). Finally, for objective measures of sleep
disorders in MS patients, nine studies using polysomnography
(PSG) [27,30,33,36,40,41,49,56,61] and two studies applying actig-
raphy [26,65] were used.
Cross-sectional data
Among the studies reporting on fatigue levels (n ¼ 40),
increased fatigue scores (e.g., FSS >4 or MFIS >34) were found in
the vast majority (78%) and were mostly well above their critical
cut-offs. Increased daytime sleepiness, as deﬁned by a mean ESS
score above 10, was detected in 11 studies (23%) reporting ESS
values in either total samples or subgroups of patients. The largest
non-systematic survey of sleep disorders in the MS population to
date, comprising 2375 patients, suggests increased daytime sleep-
iness in 30% of the respondents based on an ESS score above 10 [31]
(see Table 2). Within the patient groups, elevated mean ESS scores
mostly ranged from 10.5 to 12.5 and were close to their critical cut-
off value. Only a single study, with 21 fatigued MS patients, showed
a higher mean ESS score for the whole group (15.7) [33]. On an
individual level, the proportion of MS patients with elevated ESS
scores was up to 61% in those studies that provided frequency data
(23 studies in total). Six studies with population sizes of at least 100
MS-patients reported frequencies of increased ESS scores between
19% and 53%.
Among the 19 studies that investigated the correlation between
ESS and fatigue scores, six found no signiﬁcant correlation between
the two [28,41,47,48,53,54]. The other studies reported low [45] to
high correlations [33] (from r¼ 0.18 to 0.74) with most correlations
being in the moderate range (r ¼ 0.30 to 0.47)
[30,34,35,38,40,44,46,51,55]. Several studies using PSG or actig-
raphy found an association between an increased level of sleepi-
ness or fatigue and objectively measured sleep disorders such as
disrupted sleep/abnormal sleep cycles [26], impaired sleep quality
[33,41,49,56], periodic limb movement disorder (PLMD) [27] or
SRBD [40,61]. Only one polysomnographic study did not ﬁnd a
difference in the sleep parameters between the fatigued versus
non-fatigued MS-patients [36].
Longitudinal data
Our search yielded 16 studies reporting ESS data at baseline and
at follow-up (see Table 3). Six studies speciﬁcally evaluated the ef-
ﬁcacy of wakefulness-promoting agents (e.g., modaﬁnil or armo-
daﬁnil) on fatigue or sleepiness. In two placebo-controlled studies,
modaﬁnil [66] or armodaﬁnil [60] did not signiﬁcantly improve fa-
tigue or sleepiness at all. Among two further studies using placebo,
one demonstrated a substantial placebo effect on fatigue with no
additional beneﬁt frommodaﬁnil [68],whereas the other study only
reported signiﬁcant improvements in fatigue compared to the pla-
cebo run-in phase [67]. Two non-placebo-controlled studies with
modaﬁnil showed signiﬁcant improvement on either both fatigueus fatigue in patients with multiple sclerosis: A systematic review on
ews (2016), http://dx.doi.org/10.1016/j.smrv.2016.03.004
R.F.J. Popp et al. / Sleep Medicine Reviews xxx (2016) 1e1410and sleepiness [72] or fatigue alone [59]. The impact of other
medications focusingonvarious clinical effects (e.g., on sleepquality
or as disease-modifying immunotherapies) was assessed by ﬁve
other studies. In two placebo-controlled studies, the hypnotic agent
eszopiclone had no signiﬁcant effect on ESS or FSS [58], while the
nightly sublingual administration of the antispasmodic drug tiza-
nidine signiﬁcantly reduced next-day spasticity and was associated
with a reduction of the ESS-score. This effect was unexpected, since
day-dose tizanidine typically increases daytime hypersomnolence
[70]. In three observational studies involving immune modulatory
drugs, natalizumab improved both sleepiness and fatigue [69],
whereas interferon-beta, which may provoke sleep disturbances,
did not change [65] or even negatively affected both conditions in
the long term [63]. The injection of interferon-beta impaired sleep
efﬁciency during the following night and led to short-term effects of
sleepiness and fatigue during the next day [65].
Three of the 16 longitudinal studies investigated the effects of
sleep disorder treatment. One study showed a signiﬁcant
improvement of both fatigue and sleepiness, particularly for the
treatment of SRBD [61]. Two other studies found that either CPAP-
therapy [64] or treatment of different sleep disorders (e.g. RLS,
PLMD, insomnia, SRBD) [73] were associated with a signiﬁcant but
moderate decrease of FSS scores,whereas ESS scores did not change.
Participants of a cognitive behavioral therapy group improved
signiﬁcantly more over time (6 mo follow-up) than participants of
relaxation training, in terms of fatigue as assessed by the FSS. Such
an improvement was not found for the ESS [71]. In a single study, an
energy conservation program to manage fatigue was tested [62].
Signiﬁcant improvement of cognitive scores on the fatigue impact
scale (FIS) could be observed, but no signiﬁcant changes in all other
outcome variables, including FSS and ESS, were found.
Discussion
In our comprehensive literature search we strived to ﬁnd all
available evidence on the use of the ESS as an assessment tool in
adult patients with MS. Finally, we identiﬁed 48 studies that ful-
ﬁlled our inclusion criteria.
The majority of studies showed clinically signiﬁcant fatigue in
MS, whereas sleepiness was reported to be less frequent and less
severe. Nevertheless, a substantial number of fatigued patients
showed increased ESS scores as well. Some studies investigating
the association between sleepiness and fatigue revealed weak to
moderate correlations between both conditions, mainly depending
on the presence of comorbid sleep disorders. In general, sleep
disorders such as SRBD [61,74] or PLMD [27] and impaired sleep
quality are often associated with fatigue or sleepiness [33,56].
Importantly, the small number of available placebo-controlled,
interventional studies showed that wakefulness-promoting
agents, such as modaﬁnil or armodaﬁnil, were not consistently
effective to reduce either sleepiness or fatigue in the long-term
[60,66,68]. These ﬁndings are in line with a 2015 Cochrane data-
base review reporting weak and inconclusive evidence for the ef-
ﬁcacy of stimulants, such as modaﬁnil, pemoline or amantadine, as
pharmacological treatments for fatigue in MS [75].
The extent of sleepiness and fatigue in MS
In almost all (85%) selected studies using the ESS as an assess-
ment tool, fatigue scores (typically measured with the FSS) were
also presented. Increased fatigue in patients with MS, as indicated
by elevated fatigue rating scores, was present in the majority (78%)
of the reviewed studies that provided fatigue data. This ﬁnding is in
accordance with previous epidemiological studies that showed
high prevalence of fatigue in patients with MS [7e10].Please cite this article in press as: Popp RFJ, et al., Daytime sleepiness vers
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was observed less frequently (26% of the studies), comprising a
limited number of patients with MS (see Table 2). Two studies
reporting mean ESS scores of 15.0 and 15.7 referred to two sub-
groups that were a priori deﬁned as sleepy or fatigued comprising
only 6 (total n ¼ 12) or 11 (total n ¼ 21) MS patients, respectively
[27,33]. Of note, the study by Beran and colleagues [27] used the ESS
as a speciﬁc selection criterion (ESS score 9) for patients with and
without daytime sleepiness. In few other studies indicating path-
ological sleepiness on a group level, patients were selected
regarding fatigue (fatigue descriptive scale  5) in combination
with complaints of sleep disturbances [58]. Thiswas particularly the
case for interventional studies investigating the efﬁcacy of wake-
promoting substances [66,68]. In some other studies showing
increased ESS scores in patient subgroups, the patients had specif-
ically been selected for increased fatigue levels [26,33,39,56].
In all studies with more than 150 MS patients, the mean ESS
score did not indicate increased sleepiness. In the two largest
samples of MS patients by Mills and Young [47] (n ¼ 559 with valid
ESS data) and Brass and colleagues [31] (n ¼ 2375), the average ESS
scores were 7.9 (mean) and 8 (median), respectively e well below
the critical cut-off score. Despite the low mean ESS scores of the
study sample published by Brass and colleagues [31], 30% of the
patients scored above 10, indicating increased sleepiness. In gen-
eral, daytime sleepiness does not seem to be a prominent and
frequent symptom in MS patients on a group level, but may be
present in a substantial number of patients (ranging up to 61%) on
an individual level (Table 2).
The association of sleepiness and fatigue
The majority of studies typically showed increased fatigue
scores without overlapping sleepiness. Only one single study,
comprising no more than 14 MS patients found increased ESS
scores without corresponding elevated fatigue levels [60]. Our re-
sults indicate that fatigue without sleepiness is frequent, while
sleepiness without fatigue is rare. Thus, if pathological fatigue is
present, ESS scores can be either high or low. These ﬁndings are in
accordance with a pilot study by Merkelbach and Schulz [22],
indicating that sleepiness may vary to a noticeable extent inde-
pendently from fatigue. The authors also suggest sleep disorders as
a critical intervening factor that ampliﬁes sleepiness in a subgroup
of fatigued MS patients [46]. By extending their preliminary results
in a larger study, the authors demonstrated in a single-item analysis
of the ESS that only a subset of ESS items referring to self-paced
activation for functioning was closely associated with fatigue as
assessed by the FSS [46].
Few studies speciﬁcally distinguished between the concepts of
sleepiness versus fatigue on a semantic level [27,46], while 19
studies investigated the relationship between both clinical con-
ditions in more detail. These studies, which explored the rela-
tionship between the ESS as a main outcome parameter and
fatigue scales found mainly moderate correlations between both
conditions.
Semantic confusion of concepts
Sleepiness and fatigue are two interrelated but distinct phe-
nomena [19] that can be easily confused [76]. The terms are often
used as synonyms, both colloquially and in the scientiﬁc literature
[77]. In clinical interviews, patients with hypersomnolence often
use the term fatigue to describe their symptoms of excessive
daytime sleepiness [78]. One particular study showed that pa-
tients with narcolepsy and patients with insomnia both scored
high on the FSS when asked for symptoms of fatigue. However,us fatigue in patients with multiple sclerosis: A systematic review on
ews (2016), http://dx.doi.org/10.1016/j.smrv.2016.03.004
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propensity to fall asleep during the day assessed by the ESS [79].
In insomnia research, it is well established to differentiate be-
tween both concepts as clinical criteria, as patients with primary
insomnia complain about excessive fatigue during the day, but not
about sleepiness as deﬁned above [80]. Because the meaning of
both terms differs between languages, the assessment of fatigue
and sleepiness is even more difﬁcult. This is especially true for the
FSS, which uses the term “fatigue” without any further
speciﬁcations.
There is converging evidence that fatigue and sleepiness are two
different concepts with a limited overlap of symptoms. Because
fatigue is mostly poorly deﬁned, applied assessment tools are often
not precise enough to distinguish between both conditions [81].
Few original studies on MS (e.g., [27,46]) have explicitly distin-
guished between the concepts of sleepiness and fatigue and have
explored the relationship between both clinical conditions in more
detail. In many other studies, the terms fatigue and sleepiness are
used inconsistently, sometimes even synonymously [76]. In gen-
eral, the terms fatigue, tiredness and sleepiness are rarely explored
differentially, and their lack of distinction is a major issue in clinical
research and practice [21].
The impact of sleep disorders
Fatigue in MS appears to be multifactorial, with a component of
fatigue directly attributable to the MS disease process (primary
fatigue), as well as to secondary chronic illness factors, such as pain,
medication, depression or other comorbidities, including poor
sleep [4,82,83]. It has been reported that at least 50% of patients
with MS complain about sleep disturbances or poor sleep [5,84])
Recent studies suggest that primary sleep disorders may intensify
MS-related fatigue [31,85]. In addition, patients with MS are at an
increased risk of secondary or comorbid forms of insomnia because
common symptoms of MS (e.g., nocturia, pain, spasticity, paraes-
thesias, depression, and anxiety) often interfere with restorative
sleep. Speciﬁc sleep disorders such as RLS, PLMD, and SRBD have
also been reported to be present at higher frequencies in MS pa-
tients than in the general population [4,6,33,86]. Comorbid sleep
disorders and poor sleep are often unrecognized clinical conditions
in MS and may additionally contribute to fatigue [29,87]. This
notion is supported by the ﬁndings that treatment of different sleep
disorders, particularly SRBD, is effective to reduce fatigue in MS
[61,64,73].
The largest study included in our review comprised 2375 MS
patients and focused on the frequency of sleep disorders and
their association with fatigue and sleepiness [31]. As assessed by
the ESS, the prevalence of daytime sleepiness was reported to be
30%, while that for abnormal fatigue measures was 60%.
Increased sleepiness and fatigue scores were associated with
positive screenings for insomnia, SRBD, and RLS that showed
prevalence rates of 32%, 38%, and 37%, respectively. Thus, more
than 70% of this large MS cohort screened positive for at least
one or more sleep disorders [31]. Studies using sleep question-
naires, actigraphy or PSG found a positive correlation between
subjectively or objectively measured disrupted sleep and fatigue
in MS patients [26,27,40,48,56,61]. Kaynak and colleagues [41]
found that the total arousal index was higher in a subgroup of
fatigued patients compared to a non-fatigued group. However,
another polysomnographic study investigating sleep-related
correlates of fatigue in MS reported conﬂicting results [36]. In
the case of increased daytime sleepiness, sleep disorders asso-
ciated with hypersomnolence may be highly prevalent, yet un-
der-recognized, clinical conditions in MS contributing to
increased fatigue [29].Please cite this article in press as: Popp RFJ, et al., Daytime sleepiness vers
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Our systematic review provides a qualitative and descriptive
survey of the summarized studies that include original data. We
may have failed to identify all relevant studies as the ESS might
not be mentioned in the ﬁelds available via the databases' search
interfaces. There was noticeable heterogeneity between studies
with respect to study design, experimental procedures, and the
quality of data sets on ESS or FSS. Therefore, no meta-analysis of
effect sizes regarding sleepiness or fatigue scores was feasible for
this review. As an operational deﬁnition of daytime sleepiness, we
used sleep propensity as assessed by the ESS. However, the ESS is
a subjective rating of sleep propensity in daily life and covers only
one speciﬁc aspect of the multi-dimensional concept of sleepiness
[88]. In addition, even though the ESS is widely used as an
assessment tool in clinical practice and research, this instrument
has only modest psychometric properties. The reliability and
validity of the ESS as a unidimensional scale for sleepiness has
been questioned by a number of studies [89]. However, due to the
huge body of ﬁndings on the ESS and the knowledge of its
strengths and limitations, utilizing the ESS as an assessment tool
for evaluating sleepiness in MS seems to be an appropriate
approach. Studies on MS comparing subjective and objective
measures of sleepiness (e.g., multiple sleep latency test, mainte-
nance of wakefulness test, or pupillography sleepiness test) are
rare [27,40,41,49,90] and beyond the scope of our review but
warrant further research.
Implications for clinical practice
Sleepiness may confound measures developed to assess fatigue
(see also Table 1). In general, individuals seem to subsume sleepi-
ness under the broader notion of being tired or feeling fatigued.
Thus, if patients with MS present fatigue as chief complaints or
score high on fatigue scales, clinicians should be aware of the
heterogeneity of the various symptoms. To evaluate sleepiness and
fatigue in MS as two distinct clinical conditions, we suggest the
following approach.
Firstly, MS patients with complaints of fatigue should be
evaluated with regard to the severity and clinical signiﬁcance of
the symptoms (e.g., by using the FSS, the MFIS or other rating
scales on the impact of fatigue). Secondly, sleepiness should be
evaluated by the assessment of clinical signs of daytime sleepi-
ness and supplemented by the use of the ESS. Increased daytime
sleepiness may be indicative of sleep disorders associated with
hypersomnolence and call for speciﬁc diagnostic procedures
(ICSD-3). However, hypersomnolence can also be due to insufﬁ-
cient sleep caused by a lack of sleep hygiene or habitual short
sleep times. Even if there are no signs of elevated sleep pro-
pensity during the day (i.e., ESS 10), MS patients may complain
about fatigue due to poor sleep or sleep disturbances, which are
highly prevalent in MS [5,84]. Thus, overall fatigue or tiredness,
but not sleepiness, is a core daytime symptom of insomnia that
can perpetuate MS-related fatigue similarly to depression
[38,55,56]. As mentioned above, sleep disturbances and poor
sleep are common in MS and may contribute signiﬁcantly to
daytime fatigue.
Veauthier & Paul suggested that MS patients with fatigue
(e.g., MFIS >34) and impaired sleep quality (e.g., Pittsburgh
sleep quality index (PSQI) > 5) should undergo further sleep
evaluation and, if appropriate, sleep assessment in a sleep lab-
oratory using PSG (e.g., to distinguish between pain, spasticity,
and RLS) [6]. In cases of increased fatigue or sleepiness associ-
ated with non-restorative sleep, sleep disturbances observed by
others (e.g., heavy snoring, apneas, leg movements) or impairedus fatigue in patients with multiple sclerosis: A systematic review on
ews (2016), http://dx.doi.org/10.1016/j.smrv.2016.03.004
Research agenda
 The assessment of the prevalence of daytime sleepiness
in MS is needed. This requires a systematic epidemio-
logical study using the ESS or other questionnaires in a
large population of patients with MS focusing on the
assessment of daytime sleepiness as the inability to stay
awake and alert.
 Cross-sectional studies on distinct subtypes of MS should
take into account both concepts of fatigue and sleepiness,
using adequate and established assessment tools for
each condition.
 Longitudinal studies are necessary to clarify whether the
course of MS is related to the development of fatigue,
sleepiness or sleep disorders.
 Prospective studies following MS patients with different
subtypes should be performed to allow for the analysis of
the association between fatigue, sleepiness or potential
sleep disorders and the clinical MS status of the patients
including the severity of disability as well as MRI findings.
 Studies comparing objective assessments of daytime
sleepiness (e.g., maintenance of wakefulness test, pupil-
lography, vigilance or sustained attention tasks) with
subjective measures of sleepiness and fatigue are needed
in patients with MS.
 In MS, systematic studies using the ESS or other
screening tools for hypersomnolence are needed.
Abnormal findings should be validated using more spe-
cific assessments (e.g., polysomnography).
R.F.J. Popp et al. / Sleep Medicine Reviews xxx (2016) 1e1412daytime functioning, MS patients should also be evaluated
regarding sufﬁcient sleep quantity and symptoms of speciﬁc
sleep disorders such as RLS, PLMD, SRBD, or insomnia. Diag-
nosed sleep disorders have to be treated by sleep experts
accordingly. The use of medications causing sedation or hyper-
somnia, as well as comorbid somatic or psychiatric disorders
such as depression and anxiety, also need to be taken into ac-
count. Patients with symptomatic sleepiness may particularly
beneﬁt from wakefulness-promoting agents, activity, or daytime
naps but not from rest [21]. If clinically signiﬁcant fatigue is
primary and intrinsic to the MS pathology, therapy should focus
on fatigue-speciﬁc treatment such as energy conservation pro-
grams, cooling therapy or cognitive-behavioral therapy
[71,91,92].
Conclusions
Given the high but often underestimated prevalence of
disturbed sleep in MS, patients with MS who suffer from fatigue
that affects daily functioning should undergo a sleep evaluation if
there are any signs of poor or non-restorative sleep. Within the
prominent complaint of fatigue, sleepiness as a distinctive symp-
tom can be easily overlooked. If patients with MS report fatigue or
tiredness, speciﬁc aspects of unintentional sleep or the propensity
to fall asleep should be assessed. In this context, the ESS, as a short
and easy-to-administer questionnaire, may be used as an additional
assessment tool. The presence of daytime sleepiness can guide
diagnostic evaluations with respect to comorbid sleep disorders
associated with hypersomnolence, allowing potential treatment by
effective countermeasures of sleepiness (e.g., wakefulness-
promoting agents; avoidance of monotony, utilizing power naps,
no rest).
Although sleepiness seems to be less prevalent and less severe
than fatigue, it is present in a substantial number of patients with
MS. Yet, sleepiness and tiredness-related fatigue due to sleep dis-
turbances are both under-recognized and undertreated clinical
conditions in MS that are in need of speciﬁc diagnoses and
appropriate treatments.Practice points
 Sleepiness and fatigue are two interrelated, albeit distinct
concepts with limited overlap.
 In patients with MS, fatigue is more prevalent and severe
than daytime sleepiness.
 Fatigue without sleepiness is frequent in MS, whereas
sleepiness without fatigue is rare.
 High scores on fatigue scales are often accompanied by
increased daytime sleepiness. Therefore, the ESS should
also be applied in MS patients with increased fatigue
scores. Both clinical conditions may be associated with
sleep disorders.
 Increased sleepiness, as well as significant complaints of
fatigue and poor sleep, warrants further assessment of
potential comorbid sleep disorders or negative effects of
hypnotic use. Elevated ESS scores may be indicative of
sleep disorders associated with hypersomnolence and
demand specific treatment of daytime sleepiness.
 The clinical significance of daytime sleepiness in MS pa-
tients remains unknown; nevertheless it may be pre-
sumed that it diminishes the quality of life of the patients.
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